Cargando…

The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme

Relievers account for the majority of inhaler use and associated GHG emissions. Implementing treatment guidelines can reduce the unmet need in respiratory care by improving disease control and reducing reliever overuse and the overall carbon footprint. https://bit.ly/3zh3c2B

Detalles Bibliográficos
Autores principales:	Janson, Christer, Maslova, Ekaterina, Wilkinson, Alexander, Penz, Erika, Papi, Alberto, Budgen, Nigel, Vogelmeier, Claus F., Kupczyk, Maciej, Bell, John, Menzies-Gow, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363844/ https://www.ncbi.nlm.nih.gov/pubmed/35777767 http://dx.doi.org/10.1183/13993003.02760-2021

Ejemplares similares

Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme
por: Wilkinson, Alex, et al.
Publicado: (2022)

Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients
por: Chapman, David G., et al.
Publicado: (2021)

Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge
por: Nusair, Samir
Publicado: (2020)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference
por: Masoli, Matthew, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on tuberculosis laboratory services in Europe
por: Nikolayevskyy, Vladyslav, et al.
Publicado: (2021)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA)
por: Grote, Ludger, et al.
Publicado: (2020)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

Carbon footprint impact of the choice of inhalers for asthma and COPD
por: Janson, Christer, et al.
Publicado: (2020)

Characteristics and outcomes of health and social care workers testing positive for SARS-CoV-2 in the Tayside region of Scotland
por: Siddiqui, Moneeza K., et al.
Publicado: (2020)

Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence
por: Bell, Emily C., et al.
Publicado: (2017)

Circadian rhythm of exhaled biomarkers in health and asthma
por: Wilkinson, Maxim, et al.
Publicado: (2019)

Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
por: Trinkmann, Frederik, et al.
Publicado: (2021)

The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort
por: Waudby-West, Rupert, et al.
Publicado: (2021)

Bile acid aspiration in people with cystic fibrosis before and after lung transplantation
por: Brodlie, Malcolm, et al.
Publicado: (2015)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax
por: Nikolić, Marko Z., et al.
Publicado: (2015)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

Job strain and COPD exacerbations: an individual-participant meta-analysis
por: Heikkilä, Katriina, et al.
Publicado: (2014)

Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
por: Boutou, Afroditi K., et al.
Publicado: (2014)

Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community
por: Mori, Toru, et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Breathlessness, physical activity and sustainability of healthcare
por: Aitsi-Selmi, Amina, et al.
Publicado: (2015)

Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma
por: Ierodiakonou, Despo, et al.
Publicado: (2016)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

Respiratory decline is integral to disease progression in Huntington's disease
por: Jones, Una, et al.
Publicado: (2016)

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region
por: Blok, Nick, et al.
Publicado: (2016)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Tuberculosis prevention must integrate technological and basic care innovation
por: Mason, Paul H., et al.
Publicado: (2016)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

DNA methylation modules in airway smooth muscle are associated with asthma severity
por: Perry, Mark M., et al.
Publicado: (2018)

Chronic breathlessness: re-thinking the symptom
por: Macnaughton, Jane, et al.
Publicado: (2018)

Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union
por: van der Werf, Marieke J., et al.
Publicado: (2017)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2017)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d9rmikd64i6keeg2kcrq7773ds